Current HIV/AIDS Reports

, Volume 13, Issue 4, pp 218–225 | Cite as

Lipid Abnormalities and Inflammation in HIV Inflection

  • Nicholas T. Funderburg
  • Nehal N. MehtaEmail author
Complications of Antiretroviral Therapy (G McComsey, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Complications of Antiretroviral Therapy


Infection with the human immunodeficiency virus (HIV), and subsequent treatment with antiretroviral therapy (ART), is often associated with perturbations in lipid profiles. Furthermore, persistent inflammation, in spite of suppression of viral replication by ART, likely contributes to modifications in lipid composition and function, exacerbating risk for development of cardiovascular disease (CVD). Increased levels of several pro-inflammatory lipid species, including oxidized low-density lipoprotein (LDL) and high-density lipoprotein (HDL), have been measured in HIV-infected persons and are associated with markers of immune activation. The mechanisms linked to this bidirectional relationship in which inflammation increases lipid levels and promotes their modification, and these modified lipid species perpetuate inflammatory processes, require further investigation. Treatment with statins and other lifestyle modifications, including improvement in dietary intake and exercise, are critical to reducing CVD risk. Well-designed clinical trials that take into account the complex relationships among lipids and inflammation within persons infected with HIV need to be considered.


Antiretroviral therapy Inflammation Lipid composition Oxidized LDL Statins HDL cholesterol efflux 


Compliance with Ethical Standards

Conflict of Interest

Nicholas T. Funderburg reports grants from NHLBI and has served as consultant for Gilead Inc.

Nehal N. Mehta declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045–52.PubMedGoogle Scholar
  2. 2.
    Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13:964–75.CrossRefPubMedGoogle Scholar
  3. 3.•
    Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104–16. This excellent review describes the complex relationship between inflammation and lipid metabolism in health and disease.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS (London, England). 2003;17:1179–93.CrossRefGoogle Scholar
  9. 9.
    Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr (1999). 2008;49 Suppl 2:S79–85.CrossRefGoogle Scholar
  10. 10.
    Willig AL, Overton ET. Metabolic consequences of HIV: pathogenic insights. Curr HIV/AIDS Rep. 2014.Google Scholar
  11. 11.
    Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS (London, England). 2013;27:407–15.CrossRefGoogle Scholar
  12. 12.
    Bucher HC, Richter W, Glass TR, et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999). 2012;60:135–42.CrossRefGoogle Scholar
  13. 13.
    Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207:524–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama. 2009;302:412–23.CrossRefPubMedGoogle Scholar
  15. 15.
    McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet. 2008;372:224–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Saumoy M, Sanchez-Quesada JL, Martinez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: spiral substudy. Atherosclerosis. 2012;225:200–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Lampe FC, Duprez DA, Kuller LH, et al. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr (1999). 2010;54:275–84.CrossRefGoogle Scholar
  18. 18.
    Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224:218–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Salahuddin T, Natarajan B, Playford MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J. 2015;36:2662–5.CrossRefPubMedGoogle Scholar
  22. 22.•
    Munger AM, Chow DC, Playford MP, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retrovir. 2015;31:221–8. This manuscript describes an atherogenic lipid profile in HIV-infected donors who had a benign lipid profile based on traditional lipid measurements. These results suggest a more in depth assessment of lipid profiles in persons infected with HIV may be of value in determining CVD risk.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Andrade A, Rosenkranz SL, Cillo AR, et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013;208:884–91.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013;8, e83514.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Funderburg NTX, Playford D, Andrade M, Kuritzkes A, Lederman D, Mehta MM, et al. Treatment of HIV disease with a raltegravir-based regimen increases LDL levels, but improves HDL composition and function. 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV Barcelona, Spain, 2015.Google Scholar
  26. 26.
    Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS. 2013.Google Scholar
  28. 28.
    d’Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS (London, England). 2004;18:1811–7.CrossRefGoogle Scholar
  29. 29.
    Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (London, England). 2008;22:1615–24.CrossRefGoogle Scholar
  30. 30.
    Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis. 2006;43:1482–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS (London, England). 2003;17 Suppl 1:S65–9.CrossRefGoogle Scholar
  32. 32.
    Periard D, Cavassini M, Taffe P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46:761–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis. 2000;11:41–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci. 2008;336:402–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (London, England). 2006;20:2275–83.CrossRefGoogle Scholar
  37. 37.
    Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Crum-Cianflone NF, Weekes J, Bavaro M. Thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS patient care and STDs. 2008.Google Scholar
  40. 40.
    Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med. 2004;116:420–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med. 2005;63:129–36.PubMedGoogle Scholar
  42. 42.
    Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5, e203.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Piconi S, Parisotto S, Rizzardini G, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS (London, England). 2013;27:381–9.CrossRefGoogle Scholar
  45. 45.
    Baker JV, Neuhaus J, Duprez D, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS (London, England). 2011;25:2133–42.CrossRefGoogle Scholar
  46. 46.
    Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4.Google Scholar
  47. 47.
    Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2:99–106.CrossRefPubMedGoogle Scholar
  48. 48.
    McGillicuddy FC, de la Llera MM, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135–45.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 2009;6:455–63.CrossRefPubMedGoogle Scholar
  50. 50.
    Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365–75.CrossRefPubMedGoogle Scholar
  52. 52.
    Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006.Google Scholar
  53. 53.
    Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes. Blood. 2012.Google Scholar
  54. 54.
    Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. J Virol. 2005;79:4109–19.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS (London, England). 2008;22:2035–8.CrossRefGoogle Scholar
  56. 56.•
    Maisa A, Hearps AC, Angelovich TA, et al. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS (London, England). 2015;9:1445–57. The authors provide evidence that monocytes/macrophages from HIV-infected donors are more likely to become foam cells when exposed to pooled serum samples than are cells from HIV-uninfected donors and that these changes in macrophage function may be related to TNF-alpha.CrossRefGoogle Scholar
  57. 57.
    Akerele OA, Cheema SK. Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis. Med Hypotheses. 2015.Google Scholar
  58. 58.
    Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812–20.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155–61.CrossRefPubMedGoogle Scholar
  60. 60.
    Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073–84.CrossRefPubMedGoogle Scholar
  61. 61.
    Thorne RF, Mhaidat NM, Ralston KJ, Burns GF. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 2007;581:1227–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr. 2015.Google Scholar
  63. 63.
    Kelesidis TJ, McComsey N, Brown GA, Wang TT, Yang X, Stein OO, et al. Oxidized HDL is associated with biomarkers of inflammation and immune activation in untreated and treated HIV infection. In: Infectious diseases society of America, ID Week. (San Diego, CA).Google Scholar
  64. 64.
    Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials. 2006;7:41–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419–29.CrossRefPubMedGoogle Scholar
  66. 66.
    Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–95.CrossRefPubMedGoogle Scholar
  67. 67.
    Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116–22.CrossRefPubMedGoogle Scholar
  68. 68.
    Owens 3rd AP, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122:558–68.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Jalbert E, Crawford TQ, D’Antoni ML, et al. IL-1Beta enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable anti-retroviral therapy at risk for cardiovascular disease. PLoS One. 2013;8, e75500.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161–7.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS (London, England). 2014;28:969–77.CrossRefGoogle Scholar
  73. 73.
    Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228–38.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204:1227–36.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol. 2013;168:4039–45.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. Jama. 2012;308:379–86.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Vickers KC, Maguire CT, Wolfert R, et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res. 2009;50:1735–43.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    White HD, Simes J, Stewart RA, et al. Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc. 2013;2, e000360.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Parra S, Coll B, Aragones G, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med. 2010;11:225–31.CrossRefPubMedGoogle Scholar
  81. 81.
    Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649–54.CrossRefPubMedGoogle Scholar
  82. 82.
    Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.CrossRefPubMedGoogle Scholar
  83. 83.
    Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol. 1998;18:415–22.CrossRefPubMedGoogle Scholar
  84. 84.
    Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–94.CrossRefPubMedGoogle Scholar
  85. 85.
    Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010;5, e11765.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000–6.CrossRefPubMedGoogle Scholar
  87. 87.
    Weir JM, Wong G, Barlow CK, et al. Plasma lipid profiling in a large population-based cohort. J Lipid Res. 2013;54:2898–908.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Chiu S, Williams PT, Dawson T, et al. Diets high in protein or saturated fat do not affect insulin sensitivity or plasma concentrations of lipids and lipoproteins in overweight and obese adults. J Nutr. 2014;144:1753–9.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Wong G, Trevillyan JM, Fatou B, et al. Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. PLoS One. 2014;9, e94810.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Martinelli N, Girelli D, Malerba G, et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr. 2008;88:941–9.PubMedGoogle Scholar
  91. 91.
    Ueeda M, Doumei T, Takaya Y, et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J. 2008;72:1836–43.CrossRefPubMedGoogle Scholar
  92. 92.
    Ellims AH, Wong G, Weir JM, Lew P, Meikle PJ, Taylor AJ. Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients at intermediate risk of coronary artery disease. Eur Heart J Cardiovasc Imaging. 2014;15:908–16.CrossRefPubMedGoogle Scholar
  93. 93.
    Hodge AM, English DR, O’Dea K, et al. Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: interpreting the role of linoleic acid. Am J Clin Nutr. 2007;86:189–97.PubMedGoogle Scholar
  94. 94.
    Wu D, Ren Z, Pae M, et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol. 2007;179:4829–39.CrossRefPubMedGoogle Scholar
  95. 95.
    Yu J, Pan W, Shi R, et al. Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can J Cardiol. 2015;31:357–63.CrossRefPubMedGoogle Scholar
  96. 96.
    Hardwick JP, Eckman K, Lee YK, et al. Eicosanoids in metabolic syndrome. Adv Pharmacol. 2013;66:157–266.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr (1999). 2009;51:268–73.CrossRefGoogle Scholar
  98. 98.
    Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29:1–9.CrossRefPubMedGoogle Scholar
  99. 99.
    Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol. 2015;115:1760–6.CrossRefPubMedGoogle Scholar
  100. 100.
    Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156–64.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr (1999). 2015;68:396–404.CrossRefGoogle Scholar
  102. 102.
    Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58:588–95.CrossRefPubMedGoogle Scholar
  103. 103.•
    Nou E, Lu MT, Looby SE, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS (London, England). 2016;30:583–90. The authors provide compelling data suggesting that oxLDL, and changes in oxLDL following statin therapy, is likely on the causal pathway for immune CVD risk in HIV infection.CrossRefGoogle Scholar
  104. 104.
    Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59:1148–56.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.•
    Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey GA. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS (London, England). 2016;30:65–73. This work places oxidized LDL on the causal pathway for progression of CVD in ART-treated HIV infection. Changes in oxidized LDL levels were independently associated with changes in carotid intima media thickness, even when correcting for other risk factors.Google Scholar
  106. 106.
    Panigrahi S, Freeman ML, Funderburg NT, et al. SIV/SHIV infection triggers vascular inflammation, diminished expression of Kruppel-like factor 2 (KLF2) and endothelial dysfunction. J Infect Dis. 2015.Google Scholar
  107. 107.
    Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549–54.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  1. 1.School of Health and Rehabilitation Sciences, Division of Medical Laboratory ScienceOhio State UniversityColumbusUSA
  2. 2.Section of Inflammation and Cardiometabolic DiseasesNational Heart, Lung and Blood InstituteBethesdaUSA

Personalised recommendations